MLLT1 and Nephroblastoma: Through whole genome sequencing of pathological tissues from 82 recurrent nephroblastoma cases, the proportion of MLLT1 hotspot mutations was 6.1%, including two in the discovery set (n = 51) and three in the validation set (n = 31) (8).